Q32 Bio (QTTB) and Its Competitors Financial Analysis

Q32 Bio (NASDAQ:QTTB) is one of 1,000 public companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its competitors? We will compare Q32 Bio to related businesses based on the strength of its dividends, analyst recommendations, valuation, earnings, institutional ownership, profitability and risk.

Volatility & Risk

Q32 Bio has a beta of -0.26, suggesting that its share price is 126% less volatile than the S&P 500. Comparatively, Q32 Bio’s competitors have a beta of 1.10, suggesting that their average share price is 10% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations for Q32 Bio and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Q32 Bio	0	0	2	0	3.00
Q32 Bio Competitors	6384	18716	44590	917	2.57

Q32 Bio presently has a consensus price target of $47.50, suggesting a potential upside of 85.62%. As a group, “Pharmaceutical preparations” companies have a potential upside of 83.80%. Given Q32 Bio’s stronger consensus rating and higher probable upside, equities analysts clearly believe Q32 Bio is more favorable than its competitors.

Valuation and Earnings

This table compares Q32 Bio and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Q32 Bio	-$6.65 million	-$112.96 million	-0.73
Q32 Bio Competitors	$1.70 billion	$146.87 million	-1.40

Q32 Bio’s competitors have higher revenue and earnings than Q32 Bio. Q32 Bio is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Q32 Bio and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Q32 Bio	N/A	-102.52%	-74.91%
Q32 Bio Competitors	-2,459.06%	-249.83%	-30.60%

Insider and Institutional Ownership

31.3% of Q32 Bio shares are held by institutional investors. Comparatively, 44.6% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 16.1% of Q32 Bio shares are held by company insiders. Comparatively, 14.2% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Q32 Bio beats its competitors on 7 of the 13 factors compared.

About Q32 Bio

Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics targeting powerful regulators of the innate and adaptive immune systems to rebalance immunity in autoimmune and inflammatory diseases. Its products in the pipeline include ADX-914, a human anti-IL-7R antibody that re-regulates adaptive immune function, and ADX-097, which has in vivo biodistribution to affected tissues and organs, durable tissue pharmacokinetics and pharmacodynamics, and robust in vivo efficacy. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was incorporated in 2017 and is based in Waltham, Massachusetts.